Combined With Mefloquine, Resurrect Colistin Active in Colistin-Resistant and

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2021 Dec 13

PMID 34899672

Citations 7

Authors

Xiaodong Zhang

Yining Zhao

Luozhu Feng

Mengxin Xu

Yiru Ge

Lingbo Wang

Ying Zhang

Jianming Cao

Yao Sun

Qing Wu

Tieli Zhou

Affiliations

Soon will be listed here.

Abstract

Colistin is a polymyxin antibiotic that is widely used for the treatment of multidrug resistant (MDR) infections, as the last resort. Over the past few years, unreasonable use of antibiotics has resulted in an increase in MDR strains, including colistin-resistant . The present study aimed to explore the synergistic effects of mefloquine in combination with colistin for the treatment of colistin-resistant and . The synergistic effect of the combination of mefloquine and colistin was investigated using checkerboard method, time-killing assay, biofilm formation inhibition test, and biofilm eradication test. The study also explored the synergistic effects of this combination of drugs , using a infection model. The results for checkerboard method and time killing curve indicated that mefloquine in combination with colistin showed a good antibacterial activity. Furthermore, the combination of these two drugs inhibited biofilm formation and eradicated pre-formed mature biofilms. This synergistic effect was visualized using scanning electron microscopy (SEM), wherein the results showed that the combination of mefloquine and colistin reduced biofilm formation significantly. Further, the application of this combination of drugs to infection model significantly increased the survival rate of larvae. Altogether, the combination of mefloquine and colistin showed a good synergistic effect and , and highlighted its potential to be used as an alternative therapy for the treatment of colistin-resistant infection.

Citing Articles

In vitro synergistic effects of mefloquine combined with other antimicrobial agents on carbapenem-resistant Enterobacterales.

Zou C, Wen Z, Wang W, Gao K, Shen S, Shang L Eur J Clin Microbiol Infect Dis. 2025; .

PMID: 39964629 DOI: 10.1007/s10096-025-05060-5.

Progress in the study of mefloquine as an antibiotic adjuvant for combination bacterial inhibition treatment.

Liang X, Liu Z, Wang Y, Zhang Y, Deng W, Liu Q Front Cell Infect Microbiol. 2024; 14():1470891.

PMID: 39669268 PMC: 11634880. DOI: 10.3389/fcimb.2024.1470891.

Activity of polymyxin B combined with cefepime-avibactam against the biofilms of polymyxin B-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae in in vitro and in vivo models.

Tian M, Yan B, Jiang R, Liu C, Li Y, Xu B BMC Microbiol. 2024; 24(1):409.

PMID: 39407114 PMC: 11481319. DOI: 10.1186/s12866-024-03571-3.

1H-Pyrrole-2,5-dicarboxylic acid, a quorum sensing inhibitor from one endophytic fungus in L., acts as antibiotic accelerant against .

Liu J, Wang Z, Zeng Y, Wang W, Tang S, Jia A Front Cell Infect Microbiol. 2024; 14:1413728.

PMID: 39015339 PMC: 11250523. DOI: 10.3389/fcimb.2024.1413728.

Repurposing of the antimalarial agent tafenoquine to combat MRSA.

She P, Yang Y, Li L, Li Y, Liu S, Li Z mSystems. 2023; 8(6):e0102623.

PMID: 38047647 PMC: 10734505. DOI: 10.1128/msystems.01026-23.

References

Podoll J, Olson J, Wang W, Wang X . A Cell-Free Screen for Bacterial Membrane Disruptors Identifies Mefloquine as a Novel Antibiotic Adjuvant. Antibiotics (Basel). 2021; 10(3). PMC: 8002938. DOI: 10.3390/antibiotics10030315. View

Sharma G, Rao S, Bansal A, Dang S, Gupta S, Gabrani R . Pseudomonas aeruginosa biofilm: potential therapeutic targets. Biologicals. 2013; 42(1):1-7. DOI: 10.1016/j.biologicals.2013.11.001. View

Djordjevic D, Wiedmann M, McLandsborough L . Microtiter plate assay for assessment of Listeria monocytogenes biofilm formation. Appl Environ Microbiol. 2002; 68(6):2950-8. PMC: 123944. DOI: 10.1128/AEM.68.6.2950-2958.2002. View

Andrews J . Determination of minimum inhibitory concentrations. J Antimicrob Chemother. 2001; 48 Suppl 1:5-16. DOI: 10.1093/jac/48.suppl_1.5. View

Stefaniuk E, Tyski S . Colistin Resistance in Enterobacterales Strains - A Current View. Pol J Microbiol. 2019; 68(4):417-427. PMC: 7260631. DOI: 10.33073/pjm-2019-055. View

Zharkova M, Orlov D, Golubeva O, Chakchir O, Eliseev I, Grinchuk T . Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance?. Front Cell Infect Microbiol. 2019; 9:128. PMC: 6503114. DOI: 10.3389/fcimb.2019.00128. View

Medina E, Pieper D . Tackling Threats and Future Problems of Multidrug-Resistant Bacteria. Curr Top Microbiol Immunol. 2016; 398:3-33. DOI: 10.1007/82_2016_492. View

Fadwa A, Alkoblan D, Mateen A, Albarag A . Synergistic effects of zinc oxide nanoparticles and various antibiotics combination against clinically isolated bacterial strains. Saudi J Biol Sci. 2021; 28(1):928-935. PMC: 7785452. DOI: 10.1016/j.sjbs.2020.09.064. View

Wong W, Bai X, Sleebs B, Triglia T, Brown A, Thompson J . Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesis. Nat Microbiol. 2017; 2:17031. PMC: 5439513. DOI: 10.1038/nmicrobiol.2017.31. View

10.

Grygorcewicz B, Roszak M, Golec P, Sleboda-Taront D, Lubowska N, Gorska M . Antibiotics Act with vB_AbaP_AGC01 Phage against in Human Heat-Inactivated Plasma Blood and Models. Int J Mol Sci. 2020; 21(12). PMC: 7352404. DOI: 10.3390/ijms21124390. View

11.

Mikhail S, Singh N, Kebriaei R, Rice S, Stamper K, Castanheira M . Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019; 63(8). PMC: 6658738. DOI: 10.1128/AAC.00779-19. View

12.

Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O . Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010; 35(4):322-32. DOI: 10.1016/j.ijantimicag.2009.12.011. View

13.

Cerceo E, Deitelzweig S, Sherman B, Amin A . Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microb Drug Resist. 2016; 22(5):412-31. DOI: 10.1089/mdr.2015.0220. View

14.

Saipriya K, Swathi C, Ratnakar K, Sritharan V . Quorum-sensing system in Acinetobacter baumannii: a potential target for new drug development. J Appl Microbiol. 2019; 128(1):15-27. DOI: 10.1111/jam.14330. View

15.

Zhang J, Zhao X, Cappiello J, Yang Y, Cheng Y, Liu G . Identification of simple arylfluorosulfates as potent agents against resistant bacteria. Proc Natl Acad Sci U S A. 2021; 118(28). PMC: 8285976. DOI: 10.1073/pnas.2103513118. View

16.

She P, Wang Y, Li Y, Zhou L, Li S, Zeng X . Drug Repurposing: and Antimicrobial and Antibiofilm Effects of Bithionol Against and . Front Microbiol. 2021; 12:579806. PMC: 8138570. DOI: 10.3389/fmicb.2021.579806. View

17.

Fiaccadori E, Antonucci E, Morabito S, DAvolio A, Maggiore U, Regolisti G . Colistin Use in Patients With Reduced Kidney Function. Am J Kidney Dis. 2016; 68(2):296-306. DOI: 10.1053/j.ajkd.2016.03.421. View

18.

Brackman G, Coenye T . Quorum sensing inhibitors as anti-biofilm agents. Curr Pharm Des. 2014; 21(1):5-11. DOI: 10.2174/1381612820666140905114627. View

19.

Herrera-Espejo S, Cebrero-Cangueiro T, Labrador-Herrera G, Pachon J, Pachon-Ibanez M, Alvarez-Marin R . In Vitro Activity of Pentamidine Alone and in Combination with Antibiotics against Multidrug-Resistant Clinical Strains. Antibiotics (Basel). 2020; 9(12). PMC: 7764095. DOI: 10.3390/antibiotics9120885. View

20.

Ahmed M, Zhong L, Shen C, Yang Y, Doi Y, Tian G . Colistin and its role in the Era of antibiotic resistance: an extended review (2000-2019). Emerg Microbes Infect. 2020; 9(1):868-885. PMC: 7241451. DOI: 10.1080/22221751.2020.1754133. View